{
    "id": "dbpedia_7772_3",
    "rank": 47,
    "data": {
        "url": "https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-10_en",
        "read_more_link": "",
        "language": "en",
        "title": "EudraLex - Volume 10",
        "top_image": "https://health.ec.europa.eu/profiles/contrib/ewcms/modules/ewcms_seo/assets/images/ec-socialmedia-fallback.png",
        "meta_img": "https://health.ec.europa.eu/profiles/contrib/ewcms/modules/ewcms_seo/assets/images/ec-socialmedia-fallback.png",
        "images": [
            "https://health.ec.europa.eu/themes/contrib/oe_theme/dist/ec/images/logo/logo-ec--mute.svg",
            "https://health.ec.europa.eu/sites/default/files/styles/oe_theme_ratio_3_2_medium/public/2021-12/events-icon.jpg?h=f2329d93&itok=hZTlFYXp",
            "https://health.ec.europa.eu/sites/default/files/styles/oe_theme_ratio_3_2_medium/public/2021-12/consultations-icon.jpg?h=f2329d93&itok=JEaZM4j9",
            "https://health.ec.europa.eu/sites/default/files/styles/oe_theme_ratio_3_2_medium/public/2021-12/publications-icon.jpg?h=f2329d93&itok=vIWdGX0u",
            "https://health.ec.europa.eu/sites/default/files/styles/oe_theme_ratio_3_2_medium/public/2021-12/videos-icon.jpg?h=f2329d93&itok=6I6J09Rl",
            "https://health.ec.europa.eu/sites/default/files/styles/oe_theme_ratio_3_2_medium/public/2021-12/eurobarometers-icon.jpg?h=f2329d93&itok=FHvqf82w",
            "https://health.ec.europa.eu/themes/contrib/oe_theme/dist/ec/images/logo/negative/logo-ec--en.svg"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            "medicinal product"
        ],
        "tags": null,
        "authors": [],
        "publish_date": "2024-08-28T12:00:00+00:00",
        "summary": "",
        "meta_description": "Volume 10 of the publication \"The rules governing medicinal products in the European Union\" contains guidance documents applying to clinical trials.A…",
        "meta_lang": "en",
        "meta_favicon": "/profiles/contrib/ewcms/themes/ewcms_theme/images/favicons/ec/favicon.ico",
        "meta_site_name": "Public Health",
        "canonical_link": "https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-10_en",
        "text": "Volume 10 of the publication \"The rules governing medicinal products in the European Union\" contains guidance documents applying to clinical trials.\n\nA number of documents in Volume 10 have been revised and updated to bring them in line with the changes required by the Clinical Trials Regulation (EU) No 536/2014. Additionally, new documents were prepared to cover new aspects introduced by the same Regulation.\n\nIn order to make a distinction between documents applicable to clinical trials authorised under Directive 2001/20/EC and documents relevant to clinical trials authorised under Regulation (EU) No 536/2014, these documents are listed in two separate pages on the Eudralex Volume 10 website.\n\nDuring the transitional period, which will last until 30 January 2025, both sets of documents will apply accordingly and should be referred to respectively according to the legislation under which the Clinical trial is conducted.\n\nAt the end of the transitional period all clinical trials shall be conducted under the Regulation and should follow only the set of documents applicable to the Regulation.\n\nGuidance for the Transition of clinical trials from the Clinical Trials Directive to the Clinical Trials Regulation\n\nSet of documents applicable to clinical trials authorised under Regulation EU No 536/2014\n\nQuick guide for sponsors - Regulation 536/2014 in practice\n\nQuestions and Answers Document - Regulation (EU) 536/2014\n\nAnnex II of the Q&A provides the language requirements for part I documents. Annex III of the Q&A provides lists of Member States websites specifying national requirements and contact details for Part I and Part II application\n\nChapter I - Application and application documents\n\nTemplates documents for FORM section of the CTIS\n\nTemplate statement on compliance Regulation (EU) 2016/679: PDF/Word\n\nPart II application document templates\n\nCompensation for trial participants - Template: PDF/Word\n\nHarmonisation guidance: PDF\n\nInvestigator Curriculum Vitae template: PDF/Word\n\nDeclaration of interest template: PDF/Word\n\nSite suitability form: PDF/Word\n\nInformed consent and patient recruitment procedure template: PDF/Word\n\nCompliance with applicable rules for biological samples: PDF/Word\n\nChapter II - Safety reporting\n\nICH guideline E2F - Note for guidance on development safety update reports (September 2010)\n\nFor more guidance on safety reporting please refer to the Q&A document on the Clinical Trials Regulation in Chapter V\n\nChapter III – Quality\n\nGuideline on the responsibilities of the sponsor with regard to handling and shipping of investigational medicinal products for human use in accordance with Good Clinical Practice and Good Manufacturing Practice\n\nTemplate for the qualified person's declaration equivalence to EU GMP for Investigational Medicinal Products manufactured in third countries : PDF version - Word version (may 2013)\n\nDetailed Commission guideline of 8 December 2017 on the good manufacturing practice for investigational medicinal products pursuant to the second paragraph of the Article 63(1) of Regulation (EU) No 536/2014\n\nTemplate for IMP batch release (applicable as from the date of entry into application of Regulation (EU) No 536/2014 on Clinical Trials)\n\nUnion Basic Format for Manufacturer's Authorisation (June 2013)\n\nGuideline on the requirements to the chemical and pharmaceutical quality documentation concerning investigational medicinal products in clinical trials (revision 2 – January 2022)\n\nGuideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials (Revision 2 - January 2022)\n\nAuxiliary medicinal products in clinical trials (rev. 3, March 2024)\n\nChapter IV – Inspections\n\nGuidance for the conduct of good clinical practice inspections (August 2017)\n\nAnnex I – to guidance for the conduct of good clinical practice inspections – investigator site (September 2017)\n\nAnnex II – to guidance for the conduct of good clinical practice inspections – clinical laboratories (August 2017)\n\nAnnex III – to guidance for the conduct of good clinical practice inspections – computer systems (September 2023)\n\nAnnex IV – to guidance for the conduct of good clinical practice inspections – sponsor and CRO (August 2017)\n\nAnnex VI – to guidance for the conduct of good clinical practice inspections – record keeping and archiving of documents (June 2017)\n\nAnnex VII – to guidance for the conduct of good clinical practice inspections – bioanalytical part, pharmacokinetic and statistical analyses of bioequivalence trials (June 2017)\n\nGuidance for the preparation of good clinical practice inspections (August 2017)\n\nGuidance for the preparation of GCP inspection reports and communication of inspection findings (February 2022)\n\nGuidance for coordination of GCP inspections requested in the context of marketing authorisation applications for mutual recognition and decentralised procedures and cooperation between Member States (March 2018)\n\nAnnex V – to guidance for the conduct of good clinical practice inspections – Phase I unit (November 2022)\n\nChapter V - Additional documents\n\nGuideline on reporting serious breaches\n\nAppendix III b – Information to be submitted with a notification of a serious breach\n\nAccelerating clinical trials in the EU (ACT EU) - Delivering an EU clinical trials transformation initiative\n\nQ&A on Complex clinical trials (May 2022)\n\nThis document has been developed in close collaboration between the European Medicines Agency, the Clinical Trials Coordination Group and the Clinical Trial Expert Group. It was endorsed by those groups and by the ACT EU Steering Group.\n\nQ&A on the interface between Regulation (EU) 536/2014 on clinical trials for medicinal products for human use (CTR) and Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR)\n\nThis document has been developed and endorsed by the Medical Device Coordination Group (MDCG) and the Clinical Trial Expert Group (CTEG).\n\nQuestion and Answers on the interplay between the Clinical Trials Regulation and the General Data Protection Regulation (April 2019)\n\nThis document is applicable under the Clinical Trials Regulation except for question 11 which explains the current situation under the Clinical Trials Directive.\n\nGuideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products - EMEA/CHMP/SWP/28367/07 Rev. 1 (July 2017)\n\nGuideline for good clinical practice - ICH E6(R2) - EMA/CHMP/ICH/135/1995 (2016)\n\nRisk proportionate approaches in clinical trials (April 2017)\n\nSummaries of Clinical Trial Results for Laypersons (version 2 - February 2018)\n\nGood Lay Summary Practice Guidance\n\nEthical considerations for clinical trials on medicinal products conducted with minors\n\nGuideline on the content, management and archiving of the clinical trial master file\n\nList of national contact points\n\nChapter VI – Legislation\n\nCommission Delegated Regulation (EU) 2022/2239 of 6 September 2022 amending Regulation (EU) No 536/2014 of the European Parliament and of the Council as regards labelling requirements for unauthorised investigational and unauthorised auxiliary medicinal products for human use\n\nRegulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC\n\nCommission Implementing Regulation (EU) 2017/556 of 24 March 2017 on detailed arrangements for the good clinical practice inspection procedures pursuant to Regulation (EU) No 536/2014 of the European Parliament and of the Council\n\nCommission Delegated Regulation (EU) 2017/1569 (for linguistic versions, click here) of 23 May 2017 supplementing Regulation (EU) 536/2014 of the European Parliament and of the Council by specifying principles and guidelines for good manufacturing practice for investigational medicinal products for human use and arrangements for inspections (applicable as from the date of entry into application of Regulation (EU) No 536/2014 on Clinical Trials)\n\nCommission Implementing Regulation (EU) 2022/20 of 7 January 2022 laying down rules for the application of Regulation (EU) No 536/2014 of the European Parliament and of the Council as regards setting up the rules and procedures for the cooperation of the Member States in safety assessment of clinical trials (Text with EEA relevance)\n\nSet of documents applicable to clinical trials authorised under Directive 2001/20/EC\n\nJoint EC/EMA/HMA technical notice to sponsors regarding continuous compliance with the EU legislation for clinical trials following the withdrawal of the United Kingdom from the EU\n\nGeneral information (July 2006)\n\nChapter I - Application and application form\n\nDetailed guidance for the request for authorisation of a clinical trial on a medicinal product for human use to the competent authorities, notification of substantial amendments and declaration of the end of the trial.\n\nAnnex 1 revised : PDF version - Word version (revision 4 of November 2009 ; updated on 22 of November 2019). EudraCT Version 8.0 uses the Revision 4 dated November 2009 of the Clinical Trials Application Form (updated on November 22, 2019). For more information please refer to the EudraCT website.\n\nSubstantial Amendment Notification Form : PDF version - Word version (revision 3 of June 2010)\n\nDeclaration of the End of Trial Form : PDF version - Word version (revision 19 of June 2019)\n\nDetailed guidance on the application format and documentation to be submitted in an application for an Ethics Committee opinion on the clinical trial on medicinal products for human use (revision 1 of February 2006)\n\nDetailed guidance on the European clinical trials database (EUDRACT Database) (revision of April 2004)\n\nChapter II - Safety reporting\n\nDetailed guidance on the collection, verification and presentation of adverse event/reaction reports arising from clinical trials on medicinal products for human use (\"CT-3\")\n\nICH guideline E2F - Note for guidance on development safety update reports (September 2010)\n\nChapter III - Quality of the investigational medicinal product\n\nTemplate for the qualified person's declaration equivalence to EU GMP for Investigational Medicinal Products manufactured in third countries : PDF version - Word version (may 2013)\n\nGood manufacturing practice for investigational medicinal products\n\nGood manufacturing practices for manufacture of investigational medicinal products (February 2010)\n\nDetailed Commission guideline of 8 December 2017 on the good manufacturing practice for investigational medicinal products pursuant to the second paragraph of the Article 63(1) of Regulation (EU) No 536/2014 (applicable as from the date of entry into application of Regulation (EU) No 536/2014 on Clinical Trials)\n\nTemplate for IMP batch release (applicable as from the date of entry into application of Regulation (EU) No 536/2014 on Clinical Trials)\n\nUnion Basic Format for Manufacturer's Authorisation (October 2014)\n\nGuideline on the requirements to the chemical and pharmaceutical quality documentation concerning investigational medicinal products in clinical trials\n\nGuideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials (September 2018)\n\nGuidance on Investigational Medicinal Products (IMPs) and \"non investigational medicinal products\" (NIMPs) (rev. 1, March 2011)\n\nChapter IV - Inspections\n\nGuidance for the preparation of GCP inspections (June 2008)\n\nRecommendation on inspection procedures for the verification of good clinical practice compliance (July 2006)\n\nGuidance for the conduct of GCP inspections (June 2008)\n\nAnnex I to Guidance for the conduct of GCP inspections - Investigator site (June 2008)\n\nAnnex II to Guidance for the conduct of GCP inspection - Clinical laboratories (June 2008)\n\nAnnex III to Guidance for the conduct of GCP inspections - Computer systems (June 2008)\n\nAnnex IV to Guidance for the conduct of GCP inspections - Sponsor and CRO (June 2008)\n\nAnnex V to Guidance for the conduct of GCP inspections - Phase I Units (November 2008)\n\nAnnex VI to Guidance for the conduct of GCP inspections - Record keeping and archiving of documents (March 2010)\n\nAnnex VII to Guidance for the conduct of GCP inspections - Bioanalytical part, Pharmacokinetic and Statistical Analyses of Bioequivalence Trials (November 2008)\n\nGuidance for coordination of GCP inspections and co-operation between GCP inspectors, the reference and concerned Member States and CMD(h), in the context of the evaluation of the GCP compliance of marketing authorization applications for mutual recognition and decentralized procedures (June 2009)\n\nGuidance for exchange of GCP Inspection Reports according to Article 15(2) of Directive 2001/20/EC (revision 1 - May 2009)\n\nGuidance for the communication on GCP inspections and findings (June 2008)\n\nProcedure for standardisation of GCP inspection entries in EudraCT (November 2008)\n\nGuidance for the preparation of Good Clinical Practice inspection reports (June 2008)\n\nRecommendations on the qualifications of inspectors verifying compliance in clinical trials with the provisions of Good Clinical Practice (July 2006)\n\nChapter V - Additional information\n\nGuideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products - EMEA/CHMP/SWP/28367/07 Rev. 1 (July 2017)\n\nGuideline for good clinical practice - ICH E6(R2) - EMA/CHMP/ICH/135/1995 (2016)\n\nGuidelines on Good Clinical Practice specific to Advanced Therapy Medicinal Products(2019)\n\nGuideline on the content, management and archiving of the clinical trial master file\n\n\"Questions & Answers\" Document - Version 11.0 (May 2013)\n\nEthical considerations for clinical trials on medicinal products conducted with the paediatric population:\n\nOriginal version (2008)\n\nGuideline 2008/C168/02 on the data fields from the European clinical trials database (EudraCT) that may be included in the European database on Medicinal Products\n\nList of fields contained in the \"EudraCT\" clinical trials database to be made public, in accordance with Article 57(2) of Regulation (EC) No 726/2004 and its implementing guideline 2008/C168/02 (June 2019)\n\nGuideline 2009/C28/01 on the information concerning paediatric clinical trials to be entered into the EU Database on Clinical Trials (EudraCT) and on the information to be made public by the European Medicines Agency (EMA), in accordance with Article 41 of Regulation (EC) No 1901/2006\n\nList of fields to be made public from EudraCT for Paediatric Clinical Trials in accordance with Article 41 of Regulation (EC) No 1901/2006 and its implementing guideline 2009/C28/01 (June 2019)\n\nGuidance on posting and publication of result-related information on clinical trials in relation to the implementation of Article 57(2) of Regulation (EC) No 726/2004 and Article 41(2) of Regulation (EC) No 1901/2006\n\nTechnical guidance on the format of the data fields of result-related information on clinical trials submitted in accordance with Article 57(2) of Regulation (EC) No 726/2004 and Article 41(2) of Regulation (EC) No 1901/2006 (January 2013)\n\nEudraCT - List of additional fields contained in EudraCT (reasons for negative opinions of the Ethics Committee) (November 2010)\n\nChapter VI - Legislation"
    }
}